オプションチェーンは、Innate Pharmaの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Innate Pharmaの市場センチメントを評価します。.

Innate Pharma (NASDAQ:IPHA) 株価情報, オプションチェーン

Innate Pharma

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

Innate Pharma S.A. - American Depositary Shares

Innate Pharma SA

B of A Securities analyst Ronald Epstein maintains RTX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) with a Buy and raises the price target from $145 to $155.

News

Price Target

Analyst Ratings

B of A Securities Maintains Buy on RTX, Raises Price Target to $155

Whales with a lot of money to spend have taken a noticeably bullish stance on Applied Mat.
Looking at options history for Applied Mat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) we detected 12 trades.
If we consider the specifics of each trade, it is accurate to state that 66% of the investors opened trades with bullish expectations and 25% with bearish.
From the overall spotted trades, 2 are puts, for a total amount of $246,250 and 10, calls, for a total amount of $560,223.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $175.0 and $230.0 for Applied Mat, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Applied Mat's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Applied Mat's whale activity within a strike price range from $175.0 to $230.0 in the last 30 days. 
<h3>Applied Mat Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738258275_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMAT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/31/25</td>
<td>$6.2</td>
<td>$5.2</td>
<td>$5.2</td>
<td>$182.50</td>
<td>$130.0K</td>
<td>445</td>
<td align="right">257</td>
</tr>
<tr>
<td>AMAT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/31/25</td>
<td>$4.8</td>
<td>$4.65</td>
<td>$4.65</td>
<td>$182.50</td>
<td>$116.2K</td>
<td>445</td>
<td align="right">508</td>
</tr>
<tr>
<td>AMAT</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$6.45</td>
<td>$5.65</td>
<td>$6.0</td>
<td>$200.00</td>
<td>$96.0K</td>
<td>1.3K</td>
<td align="right">162</td>
</tr>
<tr>
<td>AMAT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$10.5</td>
<td>$10.0</td>
<td>$10.05</td>
<td>$200.00</td>
<td>$80.4K</td>
<td>1.0K</td>
<td align="right">81</td>
</tr>
<tr>
<td>AMAT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$2.0</td>
<td>$1.94</td>
<td>$2.0</td>
<td>$200.00</td>
<td>$80.0K</td>
<td>3.5K</td>
<td align="right">430</td>
</tr>
</tbody>
</table>

<h3>About Applied Mat</h3>
Applied Materials Inc is the largest semiconductor wafer fabrication equipment, or WFE, manufacturer in the world. Applied Materials has a broad portfolio spanning nearly every corner of the WFE ecosystem. Specifically, Applied Materials holds a market share leadership position in deposition, which entails the layering of new materials on semiconductor wafers. It is more exposed to general-purpose logic chips made at integrated device manufacturers and foundries. It counts the largest chipmakers in the world as customers, including TSMC, Intel, and Samsung.
<h3>Current Position of Applied Mat</h3>
<ul>
<li>Trading volume stands at 2,123,655, with AMAT's price up by 3.28%, positioned at $181.02.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 14 days.</li>
</ul>
<h3>What Analysts Are Saying About Applied Mat</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $200.4.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Susquehanna persists with their Neutral rating on Applied Mat, maintaining a target price of $165. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Equal-Weight rating on Applied Mat with a target price of $200. 
&#x2A; An analyst from Keybanc has elevated its stance to Overweight, setting a new price target at $225. 
&#x2A; Maintaining their stance, an analyst from Goldman Sachs continues to hold a Buy rating for Applied Mat, targeting a price of $202. 
&#x2A; Consistent in their evaluation, an analyst from Mizuho keeps a Outperform rating on Applied Mat with a target price of $210. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Applied Mat options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Markets

AMAT

Applied Mat Unusual Options Activity For January 30

Deep-pocketed investors have adopted a bullish approach towards Domino's Pizza (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in DPZ usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options activities for Domino's Pizza. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 63% leaning bullish and 27% bearish. Among these notable options, 5 are puts, totaling $435,174, and 6 are calls, amounting to $304,595.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $400.0 and $455.0 for Domino's Pizza, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Domino's Pizza's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Domino's Pizza's whale trades within a strike price range from $400.0 to $455.0 in the last 30 days. 
<h3>Domino's Pizza Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738258270_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DPZ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$6.3</td>
<td>$5.6</td>
<td>$5.95</td>
<td>$445.00</td>
<td>$141.7K</td>
<td align="right">31</td>
<td align="right">317</td>
</tr>
<tr>
<td>DPZ</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$6.3</td>
<td>$5.0</td>
<td>$5.0</td>
<td>$440.00</td>
<td>$125.0K</td>
<td align="right">24</td>
<td align="right">272</td>
</tr>
<tr>
<td>DPZ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$64.5</td>
<td>$61.0</td>
<td>$61.05</td>
<td>$400.00</td>
<td>$122.1K</td>
<td align="right">66</td>
<td align="right">20</td>
</tr>
<tr>
<td>DPZ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/31/25</td>
<td>$5.4</td>
<td>$5.3</td>
<td>$5.4</td>
<td>$450.00</td>
<td>$75.0K</td>
<td align="right">3</td>
<td align="right">169</td>
</tr>
<tr>
<td>DPZ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/07/25</td>
<td>$9.5</td>
<td>$8.3</td>
<td>$8.3</td>
<td>$455.00</td>
<td>$63.0K</td>
<td align="right">0</td>
<td align="right">88</td>
</tr>
</tbody>
</table>

<h3>About Domino's Pizza</h3>
Domino's is a restaurant operator and franchiser with nearly 20,600 global stores across more than 90 international markets at the end of 2023. The firm generates revenue through the sales of pizza, wings, salads, sandwiches, and desserts at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's US and Canadian restaurants. With roughly $18.3 billion in 2023 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Little Caesars, and narrow-moat Papa John's.
Having examined the options trading patterns of Domino's Pizza, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of Domino's Pizza</h3>
<ul>
<li>With a volume of 535,782, the price of DPZ is up 5.93% at $453.16. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 25 days.</li>
</ul>
<h3>Expert Opinions on Domino's Pizza</h3>
A total of 4 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $451.25.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Oppenheimer persists with their Outperform rating on Domino's Pizza, maintaining a target price of $495. 
&#x2A; An analyst from Morgan Stanley persists with their Overweight rating on Domino's Pizza, maintaining a target price of $496. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Underweight rating on Domino's Pizza with a target price of $412. 
&#x2A; An analyst from Barclays has decided to maintain their Underweight rating on Domino's Pizza, which currently sits at a price target of $402. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Domino's Pizza with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Domino's Pizza Options Trading: A Deep Dive into Market Sentiment

Investors with a lot of money to spend have taken a bullish stance on Lam Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with LRCX, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 21 uncommon options trades for Lam Research.
This isn't normal.
The overall sentiment of these big-money traders is split between 47% bullish and 47%, bearish.
Out of all of the special options we uncovered, 3 are puts, for a total amount of $214,860, and 18 are calls, for a total amount of $1,183,085.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $75.0 to $115.0 for Lam Research over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Lam Research stands at 1586.79, with a total volume reaching 12,424.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Lam Research, situated within the strike price corridor from $75.0 to $115.0, throughout the last 30 days.
<h3>Lam Research Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738258265_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LRCX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$16.0</td>
<td>$15.85</td>
<td>$15.85</td>
<td>$75.00</td>
<td>$240.9K</td>
<td>1.2K</td>
<td>181</td>
</tr>
<tr>
<td>LRCX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/31/25</td>
<td>$0.81</td>
<td>$0.8</td>
<td>$0.8</td>
<td>$79.00</td>
<td>$160.0K</td>
<td>833</td>
<td>2.2K</td>
</tr>
<tr>
<td>LRCX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/31/25</td>
<td>$3.35</td>
<td>$3.2</td>
<td>$3.35</td>
<td>$78.00</td>
<td>$155.1K</td>
<td>2.7K</td>
<td>2.0K</td>
</tr>
<tr>
<td>LRCX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/31/25</td>
<td>$3.35</td>
<td>$3.3</td>
<td>$3.3</td>
<td>$78.00</td>
<td>$104.3K</td>
<td>2.7K</td>
<td>1.9K</td>
</tr>
<tr>
<td>LRCX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/31/25</td>
<td>$3.4</td>
<td>$3.35</td>
<td>$3.4</td>
<td>$78.00</td>
<td>$87.0K</td>
<td>2.7K</td>
<td>2.0K</td>
</tr>
</tbody>
</table>

<h3>About Lam Research</h3>
Lam Research is one of the largest semiconductor wafer fabrication equipment manufacturers in the world. It specializes in deposition and etch, which entail the buildup of layers on a semiconductor and the subsequent selective removal of patterns from each layer. Lam holds the top market share in etch and holds the clear second share in deposition. It is more exposed to memory chipmakers for DRAM and NAND chips. It counts as top customers the largest chipmakers in the world, including TSMC, Samsung, Intel, and Micron.
In light of the recent options history for Lam Research, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Lam Research</h3>
<ul>
<li>With a trading volume of 13,508,207, the price of LRCX is up by 8.22%, reaching $81.33.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 83 days from now.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Lam Research, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

LRCX

Decoding Lam Research's Options Activity: What's the Big Picture?

When it comes to remote work, some people are taking full advantage of the flexibility it offers – and one software engineer has taken it to the next level. <a href="https://www.reddit.com/r/overemployed/comments/1i354ox/just_hit_2_month_anniversary_with_j2_this_is/">Sharing</a> their story on Reddit's r/overemployed community, they detailed how they <a href="https://www.benzinga.com/economics/macro-economic-events/24/08/40649739/americans-are-juggling-multiple-jobs-over-60-hours-every-week-to-pay-their-bills-">added a second job</a> paying $175,000 to their already comfortable $100,000 remote role. The result? Saving $20,000 in just two months.
Here's how they did it, why they say it's worth the effort and what others in the community had to say about their approach.
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/62-years-old-with-1-mil-saved">I&#8217;m 62 Years Old And Have $1.2 Million Saved. Is This Enough to Retire Stress-Free?</a></li>
<li>The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?</li>
</ul>
<h2 class="wp-block-heading">A Leap of Faith Pays Off</h2>
For five years, they had been working a $100,000-a-year software engineering job that only required about 20 hours of actual work weekly. While the job's <a href="https://www.benzinga.com/startups/24/10/41231722/kevin-oleary-says-theres-no-worklife-balance-for-new-entrepreneurs-as-guys-in-mumbai-or-shanghai-wor">work-life balance</a> was great, they decided to test the waters of Overemployment – a strategy where people work two or more remote jobs at the same time.
"I decided to take a leap of faith and accepted J2 at $175,000," they wrote, referring to the second job. "I only expected to last a couple of weeks, but it has been surprisingly feasible." Fast forward two months and they had banked $20,000 in extra income, which they're using for a house down payment.
Trending: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $100.</a>
<h2 class="wp-block-heading">Juggling Two Jobs</h2>
How do they make it work? Both jobs are fully remote and they put in about 50 hours weekly across the two roles. &#8220;I usually do just enough work each day for both jobs that I can give a decent update at daily scrum ceremonies and then I catch up on Sundays and work a few hours for whatever job I'm behind on.&#8221;
The secret to success is focusing on completing enough work for each job to give solid updates during daily stand-ups, a common practice in software development. To stay on top of things, they use Sundays to catch up on tasks if either job falls behind during the week.
"I work much more efficiently than my coworkers, I guess," they shared. "I get assigned a task that it'd take the average dev a week to finish and I can do it in three days. I'm &#8216;active&#8217; 40 hours a week but really only work like 20."
Trending: Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a>
<h2 class="wp-block-heading">The Financial Perks – and Challenges</h2>
The financial boost has been life-changing. With the additional income, they have been able to accelerate savings goals, <a href="https://www.benzinga.com/money/buying-a-house-in-january">buy a house</a> and even treat themselves to small luxuries like <a href="https://www.benzinga.com/real-estate/24/05/38878508/millennials-coming-to-a-golf-course-community-near-you">new golf clubs</a>. But, as they admit, maintaining two jobs is challenging.
"It's Winter right now, so I&#8217;m hibernating inside anyways," they explained. "But if I make it through the spring, it's going to be tough not to leave J2. Hours are until 6 p.m. in the evening and it&#8217;s a contract, so I get no paid time off.&#8221; If they miss even one day, they&#8217;re giving up $600.
This dynamic has left them feeling a bit "trapped" by the high pay, but they're still grateful for the opportunity to build their financial cushion.
See Also: This Jeff Bezos-backed startup will allow you to <a href="https://www.benzinga.com/money/bezos-landlord-100-dollars">become a landlord in just 10 minutes, with minimum investments as low as $100</a>.
<h2 class="wp-block-heading">Advice from the OE Community</h2>
The r/overemployed community chimed in with advice and encouragement. Some suggested they "slow roll" tasks by stretching out timelines to make juggling both roles easier. Others emphasized the importance of maximizing retirement contributions and investing wisely to make the most of the extra income.
One commenter summed it up: "Make hay while the sun shines. Make sure you max your 401(k), IRA, HSA, etc. and then pile a ton of the rest into a brokerage and/or mortgage."
Another user warned about burnout and recommended finding a sustainable pace. "Tailor your throughput to your team," they advised. "Do exactly enough."
Read Next:
<ul>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
<li><a href="https://www.benzinga.com/money/mark-cubans-annuity-adv">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a></li>
</ul>

'Surprisingly Feasible' – Software Engineer Shares How A $175K Second Job Helped Him Save $20K In Just Two Months

B of A Securities analyst David Barden maintains T-Mobile US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) with a Buy and raises the price target from $240 to $255.

TMUS

B of A Securities Maintains Buy on T-Mobile US, Raises Price Target to $255

The U.S. telecom sector has delivered a robust performance over the past year, outpacing broader market gains. The S&amp;P Telecom Select Industry Index surged around 37% over the past year, significantly outperforming the <a href="https://www.benzinga.com/general/market-summary/24/12/42751664/sp-500-ends-2024-23-higher-experts-see-double-digit-growth-for-2025">S&amp;P 500's 22.95% gain</a>. 
This strength has inevitably seeped into telecom-focused ETFs, making them attractive investment avenues. Here are three ETFs that could be a door for investors to ride this wave:
Strong gains in several telecom ETFs speak of the sector's bullish momentum:
<ul>
<li>Vanguard Communication Services ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOX#NYSE">VOX</a>): Up 10% over the past three months and 31.36% over the past year.</li>
<li>Fidelity MSCI Communication Services Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCOM#NYSE">FCOM</a>): Climbed 9.83% in the past three months and 31.52% over the past year.</li>
<li>iShares U.S. Telecommunications ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/IYZ#BATS">IYZ</a>): Gained 6.7% over three months and 15% in a year.</li>
</ul>
Also Read: <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/01/43331404/top-3-tech-and-telecom-stocks-that-could-lead-to-your-biggest-gains-this-quarter">Top 3 Tech And Telecom Stocks That Could Lead To Your Biggest Gains This Quarter</a>
The telecom sector's outlook remains optimistic, considering the positive forecasts in artificial intelligence. Moreover, interest rate cuts throughout 2024, and President Trump&#8217;s push for further rate reductions, could support positive sentiments and hence, industry growth.
Notably, telecom giants AT&amp;T (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>), Verizon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>), T-Mobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) and Comcast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMSCA#NASDAQ">CMSCA</a>) reported relatively healthy Q4 earnings, reinforcing investor confidence:
<ul>
<li>Comcast<a href="https://www.benzinga.com/25/01/43335926/comcast-q4-earnings-beats-estimates-peacock-subscribers-surge-29-dividend-raised-15-billion-buyback-approved"> exceeded Wall Street's expectations</a>, driven by strong broadband revenues, despite customer losses. Earnings per share (EPS) is at 96 cents adjusted revenue at $31.92 billion; net income was $4.78 billion, up 47% year over year, and adjusted EBITDA growth of 10%.</li>
<li>Verizon's Q4 results reflected healthy growth, with both revenue and earnings <a href="https://www.benzinga.com/news/earnings/25/01/43189382/verizon-q4-earnings-revenue-beat-1-million-mobile-and-broadband-subscriber-adds-business-segment-margin-expands">surpassing estimates</a>. Its EPS was recorded at $1.10 adjusted, revenue at $35.68 billion, and net Income at $5.11 billion, rebounding from a loss a year ago.</li>
<li>AT&amp;T reported <a href="https://www.benzinga.com/25/01/43230968/att-q4-earnings-307k-fiber-adds-projects-mid-teens-broadband-growth-in-2025">strong subscriber growth</a> and operational efficiency gains, with EPS and revenues at $0.54 and $32.3 billion respectively. Net Income of $4.03 billion nearly doubled from a year ago.</li>
<li>T-Mobile&#8217;s stock gained after it reported <a href="https://www.benzinga.com/news/earnings/25/01/43300596/t-mobile-q4-earnings-beats-estimates-adds-1-9-million-postpaid-customers-targets-6-million-new-customers-in-2025">strong fourth-quarter results</a>, surpassing analyst expectations. Its EPS was $2.57, and revenue came in at $21.87 billion.</li>
</ul>
U.S. telecom ETFs remain well-positioned for continued growth thanks to strong corporate earnings and an optimistic industry outlook.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/new-etfs/25/01/43335143/peo-alphaquest-tidal-launch-etf-with-private-equity-inspired-strategy-thematic-appeal">PEO, AlphaQuest, Tidal Launch ETF With Private Equity-Inspired Strategy, Thematic Appeal</a></li>
</ul>
Photo: Shutterstock

Sector ETFs

ETFs

CMSCA

FCOM

iShares Dow Jones US Telecommunications Sector Index Fund

Telecom ETFs Gain Momentum As Sector Giants AT&T, Verizon, T-Mobile Reinforce Investor Confidence

HC Wainwright &amp; Co. analyst Ed Arce reiterates Inventiva (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVA#NASDAQ">IVA</a>) with a Buy and maintains $13 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Inventiva, Maintains $13 Price Target

Roper Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROP#NASDAQ">ROP</a>) shares are <a href="https://www.benzinga.com/pressreleases/25/01/g43331658/roper-technologies-announces-2024-financial-results">trading higher on Thursday</a>.
The company reported fourth quarter adjusted earnings per share of $4.81, beating the street view of $4.73. Quarterly sales of $1.877 billion outpaced the analyst consensus estimate of $1.829 billion.
Revenue increased by 16%, with a 9% contribution from acquisitions and a 7% increase in organic revenue.
"We grew free cash flow 16% to $2.3 billion, surpassing the $2 billion milestone for the first time in our history,&#8221; said Neil Hunn, Roper Technologies&#8217; President and CEO.
The company exited the quarter with cash and equivalents worth $188.2 million, and net inventories worth $120.8 million.
Also Read: <a href="https://www.benzinga.com/general/travel/25/01/43343648/all-60-passengers-4-crew-members-onboard-american-airlines-jet-feared-dead-after-midair-collision-official-says">64 Killed In American Airlines Midair Collision Near D.C., Worst US Air Disaster Since 2001</a>
&#8220;We deployed $3.6 billion of capital toward high-quality vertical software acquisitions, highlighted by Procare Solutions, a leading early childhood education software company, and Transact Campus, which was successfully combined with our CBORD education &amp; healthcare software business,&#8221; Hunn added.
Roper Technologies' long-term debt (net of current portion) as at quarter end was $6.579 billion, higher than $5.830 billion in the year-ago period.
Outlook: Roper Technologies expects FY25 adjusted earnings per share to be between $19.75 and $20.00, <a href="https://www.benzinga.com/calendars/guidance">slightly below the $20.06 estimate.</a>
For the first quarter, the company anticipates adjusted EPS in the range of $4.70 to $4.74, compared to the $4.84 estimate.
Price Action: ROP shares are trading higher by 6.882% to $580.36 at last check Thursday.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/01/43320124/microsoft-shares-slide-after-q2-results-cloud-revenue-misses-expectations-details" target="_blank" rel="noreferrer noopener">Microsoft Shares Slide After Q2 Results, Cloud Revenue Misses Expectations: Details</a></li>
</ul>

Earnings

Equities

Guidance

Movers

General

Roper Technologies Q4 Earnings Beat, Surpasses $2 Billion Cash Flow Milestone

B of A Securities analyst Robert Ohmes maintains Harley-Davidson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOG#NYSE">HOG</a>) with a Buy and lowers the price target from $40 to $35.

B of A Securities Maintains Buy on Harley-Davidson, Lowers Price Target to $35

Benchmark analyst David Williams reiterates MaxLinear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MXL#NASDAQ">MXL</a>) with a Buy and maintains $28 price target.

Benchmark Reiterates Buy on MaxLinear, Maintains $28 Price Target

Quest Diagnostics Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) shares are trading higher Thursday after the company reported better-than-expected financial results <a href="https://www.benzinga.com/pressreleases/25/01/n43331467/quest-diagnostics-reports-fourth-quarter-and-full-year-2024-financial-results-provides-guidance-fo">for the fourth quarter</a>.
What Happened: Quest Diagnostics reported fourth-quarter revenue of $2.62 billion, beating analyst estimates of $2.58 billion, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The company reported fourth-quarter adjusted earnings of $2.23 per share, beating estimates of $2.19 per share. 
Total revenue was up 14.5% year-over-year, while earnings grew 14.7% year-over-year. 
Quest&#8217;s board authorized a 6.7% increase to the company&#8217;s quarterly dividend from 75 cents to 80 cents. The dividend will be payable on April 21 to shareholders of record as of April 7. 
&#8220;In the&nbsp;fourth quarter, we delivered impressive revenue growth of nearly&nbsp;15%, including approximately&nbsp;5%&nbsp;organic growth, while also improving our profitability,&#8221; said&nbsp;Jim Davis, chairman, president and CEO of Quest Diagnostics.
&#8220;For the full year, we drove revenue growth of close to&nbsp;7%, including approximately&nbsp;3%&nbsp;from organic growth. Our team completed eight acquisitions, including LifeLabs in&nbsp;Canada, expanded our advanced diagnostics portfolio, and extended our geographic and market reach with new clinical, consumer and health plan customers.&#8221;
See Also:<a href="https://www.benzinga.com/25/01/43342968/intel-q4-earnings-preview"> Intel Q4 Earnings Preview: CEO Search, PC Demand, Spinoffs On Watch</a>
Outlook: Quest Diagnostics expects full-year 2025 revenue to be in the range of $10.7 billion to $10.85 billion. The company expects earnings to be in the range of $8.34 to $8.59 per share, versus estimates of $8.82 per share. 
&#8220;Our&nbsp;guidance&nbsp;for 2025 reflects our confidence in the core strength of our business, continuing robust utilization, and the momentum from acquisitions completed in 2024,&#8221; Davis added.
DGX Price Action: <a href="http://benzinga.com/quote/dgx">Quest Diagnostics shares</a> were up 6.01% at $164.78 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
This illustration was generated using artificial intelligence via Midjourney.

Quest Diagnostics Delivers Q4 Earnings Beat: The Details

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates Atossa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATOS#NASDAQ">ATOS</a>) with a Buy and maintains $7 price target.

ATOS

HC Wainwright & Co. Reiterates Buy on Atossa Therapeutics, Maintains $7 Price Target

B of A Securities analyst Wamsi Mohan maintains IBM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) with a Buy and raises the price target from $260 to $270.

B of A Securities Maintains Buy on IBM, Raises Price Target to $270

Earlier: Quest Diagnostics Sees FY25 Revenue $10.70B-$10.85B Vs $10.672B Est.

Reported Earlier, Quest Diagnostics Sees FY25 Adj. EPS $9.55-$9.80 Vs $9.75 Estimate

MSFC

MSFT

CORRECTION: Microsoft ticker Is 'MSFT'

WIIM

Microsoft shares are trading lower following Q2 earnings and Q3 outlook.

B of A Securities analyst Alice Xiao maintains Victoria's Secret (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) with a Underperform and lowers the price target from $40 to $35.

VSCO

B of A Securities Maintains Underperform on Victoria's Secret, Lowers Price Target to $35

HC Wainwright &amp; Co. analyst Heiko Ihle maintains McEwen Mining (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUX#NYSE">MUX</a>) with a Buy and lowers the price target from $19 to $18.

HC Wainwright & Co. Maintains Buy on McEwen Mining, Lowers Price Target to $18

Innate Pharma (IPHA) announced the publication in Science Immunology of preclinical data demonstrating the potential of IPH6501, Innate's proprieta...

Innate Pharma publishes IPH6501 data in Science Immunology

Innate Pharma: Looking Like A Company We'll Regret Ignoring

Innate Pharma (IPHA) with the Institute for Follicular Lymphoma, or IFLI, announced that they have entered into an agreement to clinically study th...

Innate Pharma partners with IFLI to study IPH6501, to receive $3M upfront

Innate Pharma presents lacutamab improved health-related quality of life data at ASH 2024

Innate Pharma (IPHA) announced new data highlighting the quality-of-life improvements observed in patients with cutaneous T-cell lymphoma, or CTCL,...

Innate Pharma announces new data from TELLOMAK study

Analyst Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Innate Pharma (IPHA – Research Report) and keeping the price target ...

Positive Outlook for Innate Pharma: Buy Rating Supported by Promising Lacutamab Phase 2 Results and Strong Financial Position

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

Analyst Swayampakula Ramakanth of H.C. Wainwright maintained a Buy rating on Innate Pharma (IPHA – Research Report), retaining the price target of ...

Innate Pharma: Promising Pipeline and Strategic Initiatives Support Buy Rating

In a report released on January 17, Sean Lee from Citi reiterated a Buy rating on Innate Pharma (IPHA – Research Report), with a price target of $1...

Citi Keeps Their Buy Rating on Innate Pharma (IPHA)

Innate Pharma (IPHA) announced the first patient was dosed in its Phase 1 study, investigating the safety and tolerability of IPH4502, an Antibody-...

Innate Pharma doses first patient in IPH4502 study

AGIO

CMRX

IPHA

IPHYF

MCRB

Press Releases

Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501

Innate Pharma Releases Its 2025 Financial Calendar

Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024

Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular Lymphoma

Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma

Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Innate Pharma Announces Transformative Strategy to Accelerate Growth

Number of Shares and Voting Rights of Innate Pharma as of December 31, 2024

Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York

Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors

Comments

Innate Pharma

Innate Pharma (IPHA) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル